Borel Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

https://www.thelancet.com/journals/lanrhe/art...9/fulltext

Also existing trial, primary endpoint completion estimated June 30 2020

https://clinicaltrials.gov/ct2/show/NCT043569...mp;rank=11


Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 278 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective, multi-center, randomized,double blind, placebo-controlled trial
Masking: Double (Participant, Investigator)
Masking Description: Subjects who meet all inclusion criteria and none of the exclusion criteria will be randomized 2:1 to tocilizumab or placebo.
Primary Purpose: Treatment
Official Title: Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19
Actual Study Start Date : April 20, 2020
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : August 30, 2020